Citations

Clear

152 citation(s) found for "Tobin, M D".

Using Electronic Health Records to Classify Cancer Site and Metastasis
Ruddy, Kathryn J. , Pachman, Deirdre R. , Grzegorczyk, Veronica , Rahman, Parvez, Tobin, Kyle A., Chlan, Linda L., Marsolo, Keith , Lam, Veronica , Rahman, Parvez A, Kroenke, Kurt , Herrin, Jeph , Tobin, Kyle A., Griffin, Joan M. , Austin, Jessica D. , Ridgeway, Jennifer L. , Mitchell, Sandra A , Cheville, Andrea

Mayo Clinic

Applied Clinical Informatics | June 19, 2025 | Volume: 16 | Issue: 03 | Pages: 556-568

10.1055/a-2544-3117 | PMID 40533095 Get It

AbstractThe Enhanced EHR-facilitated Cancer Symptom Control (E2C2) Trial is a pragmatic trial testing a collaborative care approach for managing common cancer symptoms. There were challenges in identifying cancer site and metastatic status.This study compares three different approaches to determine cancer site and six strategies for identifying the presence of metastasis using EHR and cancer registry data.The E2C2 cohort included 50,559 patients seen in the medical oncology clinics of a large health system. SPPADE symptoms were assessed with 0 to 10 numeric rating scales (NRS). A multistep process was used to develop three approaches for representing cancer site: the single most prevalent International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) code, the two most prevalent codes, and any diagnostic code. Six approaches for identifying metastatic disease were compared: ICD-10 codes, natural language processing (NLP), cancer registry, medications typically prescribed for incurable disease, treatment plan, and evaluation for phase 1 trials.The approach counting the two most prevalent ICD-10 cancer site diagnoses per patient detected a median of 92% of the cases identified by counting all cancer site diagnoses, whereas the approach counting only the single most prevalent cancer site diagnosis identified a median of 65%. However, agreement among the three approaches was very good (kappa > 0.80) for most cancer sites. ICD and NLP methods could be applied to the entire cohort and had the highest agreement (kappa = 0.53) for identifying metastasis. Cancer registry data was available for less than half of the patients.Identification of cancer site and metastatic disease using EHR data was feasible in this large and diverse cohort of patients with common cancer symptoms. The methods were pragmatic and may be acceptable for covariates, but likely require refinement for key dependent and independent variables.
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics
Banks, Samantha A. , Mandrekar, Jay , Jahanian, Omid , Ali, Farwa , Sagen, Jessica, Spence, Robert, Gossman, Kellie A, Kantarci, Orhun H. , Pittock, Sean J. , Pittock, S J , Jahanian, Omid , Pittock, Sean J , Baker, Matthew R , Flanagan, E P , Keegan, B Mark , Tobin, W Oliver , Banks, Samantha , Howe, Charles L. , Spence, Robert, Baker, Matthew , Flanagan, Eoin P. , Keegan, B. Mark , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 16, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1177/20552173251329825 | PMID 40292035 Get It

Background Falls in people with multiple sclerosis (pwMS) lead to morbidity and expense. Objective Identify clinical metrics associated with falls. Methods Eighty-six pwMS completed fall surveys, timed 25-foot walk (T25FW), and motion analysis with Clario Opal devices. Logistic regression models were created. Results Median age was 54.5 years (range 21–73), 62% (53) were female. The cohort included 58% with relapsing (50) and 42% with progressive MS (36). Those who reported falling in the last year were older (median age 58 vs 52.5, p = .03) and had a higher Patient Determined Disease Step (PDDS) score (median 3 vs 1, p < .0001). Falls were associated with worse balance metrics including sway area (median 2.3 degrees 2 vs 1.2, p = .01), jerk (median 3.3 m 2 /s 5 vs 1.6, p = .005), and slower T25FW (median 11.5 s vs 8; p < .0001). A multivariable regression model based on gait aid use and T25FW time >10.8 s (c = 0.80) was derived. Having both features portended a probability of falling of 0.97, while having neither, a probability of 0.26. Conclusions Falls in pwMS are more frequent in patients who are older, have higher PDDS, slower walking, and worse balance. Gait aid use and T25FW >10.8 s were strongly associated with falls in the past year.
Tremor and Disability Outcomes After Deep Brain Stimulation for Multiple Sclerosis-associated Tremor (P12-1.014)
Permezel, Fiona , Jackson, Lauren , Kantarci, Orhun H. , Keegan, Mark , Pittock, Sean J, Miller, Kai J. , Klassen, Bryan T. , Banks, Samantha A. , Baker, Matthew , Flanagan, Eoin P. , Tobin, W. Oliver , Pittock, Sean J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210835 Get It

Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder: Frequency and Type of Cancer Co-Existence, Antigen Expression and Proof of Paraneoplastic Phenotype (P11-8.018)
Kothapalli, Naga Pradyumna, Wingerchuk, Dean M. , Dubey, Divyanshu , Lassus, Fernando Cuascut, Patel, Hemali , Keegan, Mark , Sánchez, Cristina Valencia, Lucchinetti, Claudia F. , Pittock, Sean J, Guo, Yong , Flanagan, Eoin P. , Dubey, Divyanshu , Tisavipat, Nanthaya , Tobin, W. Oliver , Pittock, Sean J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000209063 Get It

Causes of Neurologic Decline in Patients with Histiocytic Neoplasms with Suspected Neurodegenerative Disease (P1-6.017)
Barmada, Amir , Go, Ronald S. , Benson, John C. , Goyal, Gaurav , Tobin, W. Oliver

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211237 Get It

7T MRI Study of Cortical and Thalamic Atrophy in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and Multiple Sclerosis (S3.010)
Morris, Pearse , Chen, John , Tillema, Jan-Mendelt , Cacciaguerra, Laura , Fagan, Andrew , Port, John D. , Tobin, W. Oliver , Flanagan, Eoin P. , Tillema, Jan‐Mendelt

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211775 Get It

Myotonic Dystrophy (DM) Burden of Disease: A Retrospective Study of Healthcare Costs and Utilization by Individuals With DM
Martinez‐Thompson, Jennifer M. , Dykhoff, Hayley J. , Sangaralingham, Lindsey R. , White, Molly, Selcen, Duygu , Martinez-Thompson, Jennifer M , Tobin, W. Oliver , Borah, Bijan J.

Mayo Clinic

Muscle & Nerve | February 19, 2025 | Volume: 71 | Issue: 6 | Pages: 972-978

10.1002/mus.28374 | PMID 39967376 Get It

ABSTRACTIntroduction/AimsHealthcare utilization and costs in myotonic dystrophy (DM) are not well understood. This study describes the burden of DM and its associated costs.MethodsWe performed a retrospective study using data from a large U.S. administrative claims database to identify commercially insured individuals with DM and compared healthcare utilization and cost with a matched cohort. Analyses were performed between the cohorts with ≥ 3 years of insured follow‐up.ResultsWe identified 1182 DM individuals with coverage at least 3 year prior and 3 years following an index DM diagnosis from January 1, 2009 to December 31, 2018. Compared to controls, DM individuals were 3.7 times more likely to be hospitalized (p < 0.0001), 2.4 times more likely to visit an emergency department (p < 0.0001), and had twice as many outpatient visits (p < 0.0001) in the first year post‐diagnosis, with similar utilization at 2‐ and 3‐years post‐diagnosis. Annual mean costs were 3.9 times higher for health plan paid costs (p < 0.0001) and 2.6 times higher for patient‐paid costs (p < 0.0001) for DM individuals than controls in the first year post‐diagnosis, with similar costs at 2‐ and 3‐years post‐diagnosis. Factors associated with higher costs included the need for durable medical equipment, including gait aids or respiratory support devices.DiscussionIndividuals with DM experience significantly higher healthcare utilization and associated healthcare costs than controls of similar age, sex, race, and census region. The findings show the high clinical and economic burden of DM, highlighting the importance of improving cost‐effective care delivery in this population.
Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
Negaard, Brianna J, Chartier, Loïc , Guerra, Luca, Haddadi, Sara , Black, Harrison, Trevis, Thomas , Tong, Tsz Hung, Moalem, Kamilia , Johnston, Anna , Hampel, Paul J. , Johnson, Jeffrey S. , Elizabeth, Steinepreis, Yang, Pinguang, Kosciejew, Serena, Elizabeth, Gould, Manos, Kate , Nowakowski, Grzegorz S. , Hodges, Georgina, Flowers, Christopher R. , Lossos, Izidore S. , Ansell, Stephen M., Mondello, Patrizia , Gysbers, Brianna J. , Arcaini, Luca , Tobin, Joshua W.D. , Link, Brian K. , Feldman, Andrew L. , Chihara, Dai , Casulo, Carla , Cottereau, Anne-Ségolène , Olson, Joshua, Romancik, Jason T. , Black, Harrison, Mou, Eric , Cheah, Chan Y. , Salvaris, Ross , Habermann, Thomas M. , Martin, Peter, Kahl, Brad S. , Nastoupil, Loretta J. , Talaulikar, Dipti , Trotman, Judith , Cerhan, James R. , Burack, Richard , Luminari, Stefano , Morschhauser, Franck , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3007-3007

10.1182/blood-2024-202088 Get It

Background: Positron emission tomography (PET) scan is the imaging modality of choice for initial staging and response assessment of follicular lymphoma (FL). Quantitative parameters such as standardized uptake value (SUV) have been investigated as putative prognosticators in FL, with high baseline SUVmax predicting aggressive disease. To date, there is no data to guide treatment choices in patients (pts) with high SUVmax but with no documented evidence of histologic transformation (HT). Specifically, it remains unclear whether anthracycline-containing regimens, such as R-CHOP, are more beneficial than R-Bendamustine (BR) in these pts. Therefore, we aimed to compare the efficacy of frontline R-CHOP and BR in newly diagnosed FL pts based on the SUVmax at baseline PET (bPET). Patients and Methods: Pts with newly diagnosed, biopsy-proven FL1-2 and FL3A who had a bPET scan and who received either first-line R-CHOP or BR within 6 months of diagnosis between 2002 and 2022 were evaluated. Analysis was restricted to pts with age &lt; 70 years to reduce confounding of age with treatment selection. Cohorts included were the FOLL12 (n=562, Luminari et al JCO 2022) and the R-chemotherapy arm of the RELEVANCE (n=216, Morschhauser et al NEJM 2018) clinical trials, the prospectively enrolled Molecular Epidemiology Resource (MER) and the Lymphoma Epidemiology of Outcomes (LEO) cohorts (n=288) and a retrospective cohort from 13 Australian centers (n=219). Choice of chemotherapy regimen was per treating physician. Maintenance was per protocol (FOLL12/RELEVANCE) or per treating physician (MER/LEO/Australia). Event-free survival (EFS) and overall survival (OS) were defined as time from treatment initiation to progression, relapse, retreatment or death; both were censored at 72 months due to varying follow-up across cohorts. SUVmax was grouped by tertile within each cohort to account for potential differences in SUVmax distributions and patient populations across cohorts. Kaplan Meier curves and multivariable Cox models cohort-stratified and adjusted for clinical factors (FLIPI, ECOG PS, age, grade 3A) were used to evaluate outcomes. Results: The median age at diagnosis was 57 years (IQR 49-64). 651 (51%) pts were treated with R-CHOP and 634 (49%) with BR. Within the study cohorts, there was a prevalence of cases receiving BR compared to R-CHOP in the Australian (90% vs 10%) and MER/LEO (68% vs 32%) cohorts, while the opposite was observed in the RELEVANCE (16% vs 84%) and FOLL12 (37% vs 63; p&lt;0.001) trials. Pts receiving R-CHOP were slightly younger (median 56 vs 58 years, p=0.005), more frequently had grade 3A (17% vs 7%, p&lt;0.001), elevated LDH (27% vs 22%, p=0.029), bulky disease &gt; 7 cm (44% vs 37%, p=0.019), lower ECOG PS (PS &gt;1 7% vs 13%, p&lt;0.001), and higher rate of high risk FLIPI (37% vs 30%, p=0.005). Baseline SUVmax was slightly lower in R-CHOP (median 10.7, IQR 7.9-14.9) vs BR (median 11.0, IQR 8.2-14.2) treated pts (p=0.0045). At a median follow-up of 56 months (range, 1-72 months), 415 pts (32%) had an event and 103 (8%) died. Higher SUVmax was not associated with EFS (middle tertile HR=0.96, 95% CI 0.76-1.22; upper tertile HR=0.86, 95% CI 0.68-1.09; p=0.45) or OS (middle tertile HR=1.28, 95% CI 0.80-2.05; upper tertile HR=0.97, 95% CI 0.59-1.59; p=0.44) in multivariable models stratified on cohort and adjusted for treatment and clinical factors. We then compared outcomes by treatment within tertiles of SUVmax. In multivariable models, R-CHOP had modestly inferior EFS to BR in low (HR=1.27, 95% CI 0.84-1.93) and middle tertiles (HR=1.49, 95% CI 0.99-2.25), and modestly superior OS to BR in low (HR=0.59, 95% CI 0.23-1.47) and middle (HR=0.79, 95% CI 0.37-1.71) tertiles. Both EFS (HR=1.06, 95% CI 0.71-1.58) and OS (HR=1.02, 95% CI 0.45-2.30) for R-CHOP were similar to BR in the highest tertile. No comparisons identified a statistically significant benefit for either therapy in multivariable models when evaluating SUVmax tertile subsets. Conclusions: In this large multicenter study of newly diagnosed FL pts with bPET who received frontline immunochemotherapy, higher baseline SUVmax was not associated with inferior outcomes after adjusting for treatment and clinical factors. Within the caveats of retrospective studies and confounding of treatment selection, these data provide no clear insights for SUVmax-based therapy selection in first-line follicular lymphoma pts treated with immunochemotherapy.
Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
Ruan, Gordon , Davidge‐Pitts, Caroline , Gruber, Lucinda , Sartori‐Valinotti, Julio C. , Jiang, Liuyan , Ahmed, Asra, Abeykoon, Jithma P. , Yi, Dongni , Go, Ronald S. , Bennani, N. Nora , Shah, Meera , Rech, Karen L. , Ravindran, Aishwarya , Ryu, Jay H. , Vassallo, Robert , Koster, Matthew J. , Tobin, W. Oliver , Hilal, Talal , Moustafa, Muhamad Alhaj , Goyal, Gaurav

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3181-3181

10.1182/blood-2024-193841 Get It

Background: Erdheim-Chester disease (ECD) manifests as multi-organ infiltration of clonal histiocytes with mutations primarily in the mitogen-activated protein kinase (MAPK) pathway. The revised classification of histiocytosis (2016) categorizes ECD with typical bilateral, symmetric osteosclerosis of the lower extremity long bones as classical (C) and as non-classical (NC) if otherwise. The clinical and biological significance of this classification is unclear. This study compared the clinical and genotypic findings of the 2 subtypes within a large cohort of ECD patients. Methods: We included patients seen at our institution since 1990 meeting the following criteria: A) had an ECD diagnosis based on the revised criteria by Haroche J, et al. (Blood 2020;135:1311-1318); B) completed whole-body imaging studies including long bones of the legs. Classification as C-ECD required symmetric osteosclerosis of the distal femur and/or proximal tibia/fibula. Results: A total of 145 patients were enrolled, comprising a male-to-female ratio of 2:1 (66.2% male). C-ECD was diagnosed in 77.2% of cases, and NC-ECD in 22.8%. The median age at diagnosis was similar with 58.5 years (range, 18-82) in C-ECD and 55 years (range, 20-81) in NC-ECD, (p=0.65). The most frequently affected systems included skeletal (81.4%), renal (60.0%), vascular (45.5%), cardiac (40.0%), central nervous (38.6%), sinus (37.2%), pulmonary (36.6%), and adrenal (32.4%). The numbers of organs involved were significantly higher in C-ECD compared to NC-ECD (median 5 vs 3, p&lt;0.01). Higher rates of skeletal (100% vs. 18.2%, p&lt;0.01), adrenal gland (37.5% vs. 15.2%, p=0.02), and sinus (44.6% vs. 12.1%, p&lt;0.01) involvement were observed in C-ECD. Arginine vasopressin deficiency (AVP-D) was exclusively observed in C-ECD (20.7% vs. 0%, p&lt;0.01). NC-ECD had a higher rate of cardiac involvement (69.7% vs. 31.3%, p&lt;0.01). No significant differences were found in other systems. The overall median time between onset of the first symptoms/signs to diagnosis was 15 months with no significant difference between C-ECD and NC-ECD (17.5 vs. 12 months, p=0.18). The median time to diagnosis of ECD in patients with AVP-D was 38.5 months, compared to 12 months without AVP-D (p=0.09). Genetic testing was conducted in 86.2% of patients and B-Raf proto-oncogene (BRAF) alterations were identified in 59.2% of the tested cases. BRAFV600E was more prevalent in C-ECD (61.3% vs. 21.9%, p&lt;0.01), whereas non-V600 mutations were more commonly found in NC-ECD (12.5% vs. 1.1%, p&lt;0.01). There was no significant difference in the frequency of BRAF fusions. NC-ECD patients exhibited a higher rate of MAP2K1 mutations (25.0% vs. 5.4%, p&lt;0.01). Other frequently mutated genes included KRAS (4.0%), NRAS (2.4%), and CSF1R (2.4%), although no significant difference was observed in their frequency between C-ECD and NC-ECD. Testicular involvement appeared to be more common in patients with MAP2K1 mutations (23.1% vs. 8%, p=0.08). Two patients with pathogenic CSF1R mutations both had central nervous system (CNS) involvement. Among C-ECD patients, BRAFV600E conferred a higher rate of CNS involvement (50.9% vs. 25%, p=0.01). No significant difference was observed in NC-ECD patients (71.4% vs 36%, p=0.09). Among NC-ECD cases, MAP2K1 mutations conferred a reduced risk of cardiac involvement (37.5% vs. 79.2%, p=0.03) and no such difference was observed in patients with C-ECD (40% vs 34.1%, p=0.79). The median numbers of organs involved in patients with BRAF, MAP2K1, and KRAS/NRAS mutations were 5, 3, and 3, respectively, with no significant difference. Conclusions: C-ECD affects more organs and more frequently involves bones, adrenal glands, and sinuses. AVP-D was exclusively observed in C-ECD. Conversely, NC-ECD showed a higher prevalence of cardiac involvement. BRAFV600E was more commonly identified in C-ECD, whereas non-V600 mutations and MAP2K1 mutations were more prevalent in NC-ECD. Among C-ECD patients, BRAFV600E was correlated with a greater likelihood of CNS involvement. Conversely, NC-ECD patients with MAP2K1 mutations had a reduced risk of cardiac involvement. This study highlights the distinct clinical and molecular features of C-ECD and NC-ECD, underscoring the importance of subclassifying ECD into classical and non-classical forms. Further studies are needed to explore differences in the clinical outcomes between the 2 forms.
Radiology-pathology correlation: Rosai–Dorfman disease
Benson, John C. , Pais, Alex B, Mark, Ian T. , Chen, John J. , Meyer, Frederic B., Giannini, Caterina, Tobin, William O, Benson, John , Mark, Ian , Chen, John J , Pais, Alex B, Tobin, W. Oliver , Hunt, Christopher H.

Mayo Clinic

The Neuroradiology Journal | November 20, 2024 | Volume: 38 | Issue: 3 | Pages: 299-303

10.1177/19714009241303077 | PMID 39567877 Get It

Rosai–Dorfman Disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytic neoplasm. Although the disease classically presents as massive painless lymphadenopathy in young adults, RDD can also involve the central nervous system in some patients. CNS lesions, can cause headaches, neurologic deficits, and even neurologic deficits. The imaging appearance of CNS RDD typically mimics that of meningiomas: well-circumscribed dural-based lesions that often have dural tails. However, some imaging clues also exist that might help a radiologist recognize RDD, even before histopathologic confirmation. This radiology-pathology report of a patient with CNS RDD highlights the most pertinent clinical, imaging, and pathologic features of CNS RDD, and discusses what the neuroradiologist needs to know about the disease.